Business
Cipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Board
Cipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Can...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Board\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Board\nCanada NewsWire\nMISSISSAUGA, ON, April 6, 2016\n\n\n\nMISSISSAUGA, ON, April 6, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (\"Cipher\" or \"the Company\") today announced it has received Health Canada approvals for SD Cream and AD Cream (also known as Dermadexin and Pruridexin). Both products were approved in Canada by the Natural and Non-Prescription Health Products Directorate. In addition European approval of Helioclin® Pruritus SD Cream (also known as Pruridexin) was achieved.\n\nHelioclin® Dermatitis SD Cream (also known as Dermadexin) was approved in Europe in 2014 and with the approval of Helioclin® Pruritus SD Cream last week as a Class III medical device, Cipher is now in a position to partner to launch and grow a product line with significant potential in the European market.\n\nIn Canada, the SD Cream is a patent-protected topical barrier-repair cream for the management and relief of the signs and symptoms of seborrheic dermatitis (such as erythema, scaling and pruritis). AD Cream is a patent-protected topical cream for the management and relief of the signs and symptoms of atopic and contact dermatitis (such as erythema, scaling and pruritus).\n\n\"We continue to deliver on our key regulatory milestones and our plan to expand the Canadian product portfolio,\" said Shawn O'Brien, President & Chief Executive Officer of Cipher. \"These products target chronic inflammatory conditions that we believe are insufficiently addressed today. While we finalize our commercialization plans in Canada, we are very focused on obtaining U.S. approvals for both products, which we are targeting later this year.\"\n\nCipher acquired the worldwide rights to these two products from Astion Pharma A/S in Febru...